INCY Share Price

Open 131.88 Change Price %
High 134.97 1 Day 2.81 2.14
Low 130.24 1 Week 11.66 9.53
Close 134.02 1 Month 12.30 10.11
Volume 33033217 1 Year 59.68 80.28
52 Week High 134.97
52 Week Low 60.30
INCY Important Levels
Resistance 2 138.40
Resistance 1 136.60
Pivot 133.08
Support 1 131.44
Support 2 129.64
NASDAQ USA Most Active Stocks
SPWR 8.98 1.01%
TFSL 17.20 0.17%
RIGL 2.52 9.57%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
REGN 373.05 3.34%
More..
NASDAQ USA Top Gainers Stocks
TEAR 5.74 983.02%
CGEI 0.37 85.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
IMGN 3.28 21.03%
VOXX 5.05 20.24%
HAUP 0.06 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Incyte Corporation (NASDAQ: INCY)

INCY Technical Analysis 5
As on 27th Feb 2017 INCY Share Price closed @ 134.02 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 91.37 & Strong Buy for SHORT-TERM with Stoploss of 113.59 we also expect STOCK to react on Following IMPORTANT LEVELS.
INCY Target for February
1st Target up-side 134.54
2nd Target up-side 143.88
3rd Target up-side 153.23
1st Target down-side 107.88
2nd Target down-side 98.54
3rd Target down-side 89.19
INCY Other Details
Segment EQ
Market Capital 2323686912.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.incyte.com
INCY Address
INCY
Experimental Station
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States
Phone: 302-498-6700
INCY Latest News
Interactive Technical Analysis Chart Incyte Corporation ( INCY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Incyte Corporation
INCY Business Profile
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.